Friday, May 7, 2021
CONTINENTAL BREAKFAST
7:00 - 8:00  
Introduction
8:00 - 8:15

Introduction to the Day’s Proceedings

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

SESSION 9:
Insight from large datasets of women with breast cancer
8:15 - 9:55

CHAIR: Stephen Chanock¸ MD, National Cancer Institute, Rockville, MD, USA

8:15 - 8:35

Population-based studies of breast cancer risk in association with established and candidate breast cancer susceptibility genes

Fergus Couch, PhD, Mayo Clinic, Rochester, MN, USA

8:35 - 8:55

Generation and analysis of genomic data at population level: the UK experience

Clare Turnbull, MD, PhD, MFPH, Institute of Cancer Research, London, UK

8:55 - 9:05

Proffered paper 1

9:05 - 9:15

Proffered paper 2

9:15 - 9:25

Proffered paper 3

9:25 - 9:35

Proffered paper 4

9:35 - 9:55

Question and discussion period (all speakers)

BREAK
9:55 - 10:25  
SESSION 10:
Polygenic risk scores in practice
10:25 - 11:55

CHAIR: Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

10:25 - 10:45

Polygenic risk scores and the CanRisk breast and ovarian cancer risk prediction tool

Antonis Antoniou, PhD, University of Cambridge, Cambridge, UK

10:45 - 11:05

Multifactorial breast cancer risk assessment

Paul James, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

11:05 - 11:15

Proffered paper 1

11:15 - 11:25

Proffered paper 2

11:25 - 11:45

Question and discussion period (all speakers)

CLOSING SESSION
The Marla Miller Memorial Lecture
11:55 - 13:10

Introductory Remarks

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

The Icelandic approach to population-based testing for high risk alleles for breast and ovarian cancer

Kári Stefánsson, MD, PhD, deCODE Genetics, Reykjavík, Iceland

Presentation by the Miller Family

Closingy Remarks

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

Marla Miller-Gross
Marla Miller-Gross passed away less than two years after being diagnosed with "routine" breast cancer, months shy of her fortieth birthday. Marla's courage in opting for genetic testing has touched lives far far beyond those that she befriended while living.

Out of Marla's tragedy, HBOC was born and the drive to improve the outcome of women and families with hereditary breast and ovarian cancer.